NASDAQ:CLPT ClearPoint Neuro (CLPT) Stock Price, News & Analysis $10.95 +0.71 (+6.93%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ClearPoint Neuro Stock (NASDAQ:CLPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ClearPoint Neuro alerts:Sign Up Key Stats Today's Range$10.12▼$10.8050-Day Range$10.00▼$12.2452-Week Range$9.76▼$19.22Volume103,613 shsAverage Volume316,851 shsMarket Capitalization$311.31 millionP/E RatioN/ADividend YieldN/APrice Target$19.67Consensus RatingBuy Company Overview ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Read More ClearPoint Neuro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreCLPT MarketRank™: ClearPoint Neuro scored higher than 38% of companies evaluated by MarketBeat, and ranked 759th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.Read more about ClearPoint Neuro's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.66) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ClearPoint Neuro is -12.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ClearPoint Neuro is -12.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearPoint Neuro has a P/B Ratio of 14.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ClearPoint Neuro's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.06% of the float of ClearPoint Neuro has been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in ClearPoint Neuro has recently increased by 14.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearPoint Neuro does not currently pay a dividend.Dividend GrowthClearPoint Neuro does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.06% of the float of ClearPoint Neuro has been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in ClearPoint Neuro has recently increased by 14.01%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.02 News SentimentClearPoint Neuro has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ClearPoint Neuro this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CLPT on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows2 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ClearPoint Neuro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $415,173.00 in company stock.Percentage Held by InsidersOnly 6.97% of the stock of ClearPoint Neuro is held by insiders.Percentage Held by InstitutionsOnly 30.08% of the stock of ClearPoint Neuro is held by institutions.Read more about ClearPoint Neuro's insider trading history. Receive CLPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address CLPT Stock News HeadlinesQ3 EPS Estimates for ClearPoint Neuro Lowered by B. RileyAugust 16, 2025 | americanbankingnews.comClearPoint Neuro: Biopharma Momentum Continues To BuildAugust 14, 2025 | seekingalpha.com"I'm risking my reputation on this"The wealth transfer most people will miss Whether you have $50 or $50,000, this blueprint can work for you.August 22 at 2:00 AM | Crypto 101 Media (Ad)ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comClearPoint Neuro, Inc.: ClearPoint Neuro Reports Second Quarter 2025 ResultsAugust 13, 2025 | finanznachrichten.deClearPoint Neuro Reports Record Q2 Revenue GrowthAugust 13, 2025 | msn.comClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comClearPoint Neuro Q2 2025 Earnings PreviewAugust 11, 2025 | msn.comSee More Headlines CLPT Stock Analysis - Frequently Asked Questions How have CLPT shares performed this year? ClearPoint Neuro's stock was trading at $15.38 at the start of the year. Since then, CLPT stock has decreased by 33.4% and is now trading at $10.24. How were ClearPoint Neuro's earnings last quarter? ClearPoint Neuro, Inc. (NASDAQ:CLPT) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.01. The firm earned $9.22 million during the quarter, compared to analyst estimates of $9.20 million. ClearPoint Neuro had a negative net margin of 66.15% and a negative trailing twelve-month return on equity of 94.44%. Read the conference call transcript. Who are ClearPoint Neuro's major shareholders? Top institutional investors of ClearPoint Neuro include Geode Capital Management LLC (2.23%), Lane Generational LLC (0.92%), Taylor Frigon Capital Management LLC (0.64%) and Conway Capital Management Inc. (0.59%). Insiders that own company stock include Joseph Burnett and Timothy T Richards. View institutional ownership trends. How do I buy shares of ClearPoint Neuro? Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ClearPoint Neuro own? Based on aggregate information from My MarketBeat watchlists, some other companies that ClearPoint Neuro investors own include Arista Networks (ANET), NVIDIA (NVDA), CrowdStrike (CRWD), Axon Enterprise (AXON), Advanced Micro Devices (AMD), Cadence Design Systems (CDNS) and Broadcom (AVGO). Company Calendar Last Earnings8/12/2025Today8/22/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLPT CIK1285550 Webwww.clearpointneuro.com Phone(949) 900-6833Fax949-900-6834Employees110Year FoundedN/APrice Target and Rating Average Price Target for ClearPoint Neuro$19.67 High Price Target$30.00 Low Price Target$9.00 Potential Upside/Downside+92.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.91 million Net Margins-66.15% Pretax Margin-66.11% Return on Equity-94.44% Return on Assets-51.58% Debt Debt-to-Equity Ratio1.46 Current Ratio7.30 Quick Ratio6.45 Sales & Book Value Annual Sales$31.39 million Price / Sales9.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book14.84Miscellaneous Outstanding Shares28,430,000Free Float26,446,000Market Cap$291.12 million OptionableOptionable Beta0.85 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CLPT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.